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Abstract
Background: The simultaneous occurrence of cardiovascular disease (CVD), kidney disease, and
anaemia is associated with increased morbidity and mortality. In the community setting, little data
exists about the risk associated with milder levels of anaemia when it is present concurrently with
CVD and chronic kidney disease (CKD). The aim of this study was to establish the prevalence of
CKD and anaemia in patients with CVD in the community and to examine whether the presence
of anaemia was associated with increased morbidity and mortality.
Methods: This study was designed as a retrospective cohort study and involved a random sample
of 35 general practices in the West of Ireland. A practice-based sample of 1,609 patients with
established cardiovascular disease was generated in 2000/2001 and followed for five years. The
primary endpoint was death from any cause. Statistical analysis involved using one-way ANOVA
and Chi-squared tests for baseline data and Cox proportional-hazards models for mortality data.
Results: Of the study sample of 617 patients with blood results, 33% (n = 203) had CKD while 6%
(n = 37) had CKD and anaemia. The estimated risk of death from any cause, when compared to
patients with cardiovascular disease only, was almost double (HR = 1.98, 95% CI 0.99 to 3.98) for
patients with both CVD and CKD and was over 4 times greater (HR = 4.33, 95% CI 1.76 to 10.68)
for patients with CVD, CKD and anaemia.
Conclusion: In patients with cardiovascular disease in the community, chronic kidney disease and
anaemia occur commonly. The presence of chronic kidney disease carries an increased mortality
risk which increases in an additive way with the addition of anaemia. These results suggest that early
primary care diagnosis and management of this high risk group may be worthwhile.
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Background
Chronic kidney disease (CKD) and cardiovascular disease
(CVD) often coexist and have been known to exert a bidi-
rectional effect on one another [1-4]. CKD is an estab-
lished risk factor for the development of CVD and in
patients with established cardiovascular disease, chronic
kidney disease is associated with a significantly increased
risk of cardiovascular mortality and morbidity [5-9]. The
suspected etiologic pathways behind the cardio-renal
interaction involve positive feedback loops between "car-
diorenal connectors" including (but not limited to) sym-
pathetic stimulation, the renin-angiotensin-aldosterone
system and cytokines [10]. Anaemia, a condition fre-
quently encountered in chronic disease, is an additional
mediator in the progression of either CKD and/or CVD
and it is also an independent risk factor for the onset of
cardiovascular complications [11]. The prevalence of
anaemia has been reported to occur in up to 50% of CKD
patients [12] and 51% of heart failure patients [13]
though results will vary depending on the setting, classifi-
cation of anaemia and severity of disease. The interrela-
tions between CKD, CVD, and anaemia are complex,
poorly understood, and are referred to in the literature as
the cardiorenal anaemia syndrome [14]. Each morbidity
of the cardiorenal anaemia syndrome is said to independ-
ently exert an effect by causing or worsening the other
mediators of the triad increasing the risk of adverse out-
comes including death [1,2].
Though the three bi-directional relationships between
CKD, anaemia and heart failure have been established,
the majority of this research has focused on the hospital-
ized population and in patients with recognized conges-
tive heart failure. While evidence for patients with
advanced CKD participating in renal replacement therapy
programs is quite robust, there appears to be little evi-
dence in the community population regarding the relative
and cumulative effect on prognosis of cardiovascular dis-
ease, chronic kidney disease and anaemia. Descriptions of
prognosis derived from secondary care may be mislead-
ing, due to selection biases, when managing patients in
primary care [13]. Others have previously shown that
patients entered into hospital-based trials of blood pres-
sure control after stroke have important age, gender and
blood pressure differences to patients managed in the
community after their stroke [15].
We utilised a cohort of patients, with the full spectrum of
cardiovascular disease, from a random sample of practices
in the community to establish the prevalence of CKD and
anaemia and to examine whether the presence of CKD
and anaemia was associated with increased mortality in
patients with cardiovascular disease.
Methods
Study population and measurement of renal function
The study sample consisted of a cohort of 1,609 patients
with cardiovascular disease who were identified from a
stratified random sample of 35 general practices in the
West of Ireland [16]. In order to generate this sample,
practices were randomly selected, after stratification by
practice type (single-handed or group) and location (rural
or urban), from the Health Services Executive Western
area and asked to participate in the study. Thirty five
(60%) practices chose to do so and these practices were
asked to generate a list of all their patients with estab-
lished cardiovascular disease using multiple methods
including practice disease registers, patient database
searches, prescribing records, prospective recording of
patient attendance and opportunistic practitioner recall.
Patients were defined as having cardiovascular disease if
they had a history of myocardial infarction (MI); angina;
or revascularisation by percutaneous coronary interven-
tion or cardiovascular bypass grafting. Patients were
included in the current study where data were available on
haemoglobin and creatinine status (serum sample meas-
urement from the regional laboratory within the study
period or up to 12 months prior to recruitment). Follow-
up data on the cohort were collected after a period of five
years and patients not experiencing events were censored
at this point. Data on subjects were also censored where
follow-up data ceased to be available. Renal function was
assessed using estimated glomerular filtration rate (eGFR)
calculated by the abbreviated Modified Diet in Renal Dis-
ease (MDRD) equation [17]. Patients were defined as hav-
ing chronic kidney disease if they had an eGFR of <60 ml/
min/1.73 m2 according to National Kidney Foundation
guidelines [18]. Anaemia status was assessed using full
blood count data. Patients were define, according to
WHO guideline, as having anaemia with a haemoglobin
of <12.0 g/dl for females and <13.0 g/dl for males [19].
Outcomes
The primary endpoint was death from any cause. Mortal-
ity data were collected from a search of practice records
and the General Register Office, which is the central civil
repository for records relating to Births, Marriages and
Deaths in the Republic of Ireland.
Statistical Analysis
For analysis of baseline characteristics and survival analy-
sis, patients were classified according to presence of
chronic kidney disease and anaemia. Baseline characteris-
tics were analysed with the use of one-way ANOVA for
continuous variables and Chi-square or Fisher's Exact test
for categorical variables. Patient variables included 18
baseline characteristics (Table 1). To control for the large
number of covariates, variable selection techniques were
used to identify the most parsimonious model containingBMC Cardiovascular Disorders 2009, 9:51 http://www.biomedcentral.com/1471-2261/9/51
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significant explanatory variables while including the cov-
ariate of interest (presence of chronic kidney disease and
anaemia). Cox proportional-hazards models [Backwards
elimination (with Wald criterion)] were used to evaluate
the prognostic effect of presence of chronic kidney disease
and anaemia over the study period while controlling for
all explanatory variables. Adjusted hazard ratios, catego-
rized according to level of multimorbidity, for death from
any cause were determined while adjusting for: age, gen-
der, GMS status, smoking status, systolic blood pressure,
diastolic blood pressure, total cholesterol level, previous
myocardial infarction, angina, heart failure, stroke,
peripheral vascular disease, thromboembolic events, prior
percutaneous coronary intervention, prior coronary artery







CVD & CKD & Anaemia
(n = 37)
p value*
Mean eGFR (ml/min/1.73 m2) (SD) 74.47 (13.4) 51.18 (10.3) 72.08 (11.6) 45.81 (14.5) <0.01
Mean Hb (g/dL) (SD) 14.50 (1.11) 13.95 (1.14) 11.13 (1.57) 11.05 (1.53) <0.01
Mean Age in years (SD) 64.49 (8.9) 69.74 (7.48) 66.90 (9.62) 72.64 (4.99) <0.01
Female sex (%) 27.4 60.3 39.5 63.1 <0.01
Current Smoker (%) 30.4 24.8 40.0 30.8 0.676
Previous CVD event (%)
MI 46.6 41.1 44.7 55.3 0.361
Angina 83.7 88.7 86.8 81.6 0.379
Heart Failure 8.0 11.8 7.9 10.5 0.502
Previous Co-morbidity (%)
Peripheral vascular disease 5.0 7.8 5.3 10.5 0.347
Stroke 4.4 5.9 2.6 0.0 0.481
Thromboembolism(PE, DVT, TIA) 10.3 18.1 2.6 10.5 0.012
Baseline Clinical status (SD)
Systolic blood pressure (mm Hg) 137.2 (17.7) 138.8 (19.8) 133.8 (15.5) 139.6 (21.3) 0.418
Diastolic blood pressure (mm Hg) 80.6 (9.3) 79.9 (8.7) 77.2 (10.0) 81.2 (8.4) 0.172
Total Cholesterol (mmol/L) 5.3 (0.97) 5.4 (1.0) 4.9 (0.9) 5.5 (1.4) 0.031
Baseline medication (%)
Aspirin 75.4 67.5 71.0 81.6 0.131
B-Blocker 51.0 46.3 55.3 34.2 0.170
Lipid-lowering agent 50.7 50.7 36.8 28.9 0.029
ACE Inhibitor 25.2 25.1 26.3 31.6 0.854
*p value refers to the one-way ANOVA and Chi-squared analyses comparing the 4 groupsBMC Cardiovascular Disorders 2009, 9:51 http://www.biomedcentral.com/1471-2261/9/51
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bypass grafting, use of aspirin, B-Blocker, Lipid-lowering
agent or ACE inhibitor. The assumptions underlying the
final models were checked using suitable residual plots
and interactions between presence of chronic kidney dis-
ease and anaemia and age and gender were investigated.
All statistical test values were two-sided, and a p value of
less than 0.05 was considered to indicate statistical signif-




Among the original 1,609 patients in the study, 42 (2.6%)
patients were lost to follow-up and 617 (38%) had com-
plete blood data. Median follow-up was 4.50 years (SD
0.4) and there was no significant difference in age, gender,
social status, smoking status, diabetic status and previous
cardiovascular morbidity between those patients with,
and without, complete blood data. Table 1 describes the
baseline characteristics of the patients according to pres-
ence of chronic kidney disease and anaemia. A total of
339 (54.9%) patients had cardiovascular disease only;
203 (32.9%) had cardiovascular disease and chronic kid-
ney disease; 38 (6.1%) patients had cardiovascular disease
and anaemia while 37 (6.0%) patients had cardiovascular
disease, chronic kidney disease and anaemia. Patients
with multimorbidity involving all three conditions were
significantly older, more likely to be female, have the low-
est mean eGFR and haemoglobin (Hb) levels, the highest
total cholesterol levels and were least likely to be taking a
lipid lowering agent when compared with the other
patient groups with fewer co-morbidities.
Outcomes
During follow-up there were 72 deaths and 90 cardiovas-
cular events. The risk of death from any cause [Log Rank
(Mantel-Cox) 22.08, p < 0.001] was significantly
increased in those patients with increased level of multi-
morbidity (Table 2, Figure 1). In the examination of the
relationship between the primary outcome and presence
of chronic kidney disease and anaemia, patients with car-
diovascular disease only ['CVD only'] were used as the ref-
erence group. The adjusted hazard ratios (HR) for
mortality according to presence of chronic kidney disease
and anaemia are displayed in Table 3. The estimated risk
of death from any cause, when compared to patients with
cardiovascular disease only, was almost double (HR =
1.98, 95% CI 0.99 to 3.98) for patients with both cardio-
vascular disease and chronic kidney disease and was over
4 times greater (HR = 4.33, 95% CI 1.76 to 10.68) for
patients with cardiovascular disease, chronic kidney dis-
ease and anaemia. No significant two-way interactions
were identified between multimorbidity and other factors
in the model when considering death by any cause.
Discussion
Summary of main findings
Multimorbidity is common in patients with cardiovascu-
lar disease in the community with 45% of patients also
having chronic kidney disease, anaemia or both. Anaemia
was relatively mild in this group with a mean haemo-
globin of 10.90 g/dl (SD = 1.24) for women and a mean
haemoglobin of 11.28 g/dl (SD = 1.80) for men. How-
ever, the presence of even mild anaemia with CKD was
associated with a synergistic amplification of the risk of
death. Patients with all three comorbidities had a greater
than 4 times increased risk of death when compared with
patients with CVD only.
Strengths and limitations of this study
This study describes the prevalence of CKD and anaemia
in a nationally representative community based cohort of
Table 2: Kaplan-Meier summary statistics for risk of deatha according to presence of CKD and anaemia Case Processing Summary
CKD Anaemia Multimorbidity Total N N of Events Censored
N Percent N Percent
No CKD or Anaemia 339 25% 314 92.6%
CKD 203 28% 175 86.2%
Anaemia 38 8% 30 78.9%
CKD + Anaemia 37 11% 26 70.3%
Overall 617 72% 545 88.3%
Overall Comparisons
Chi-Square df Sig.
Log Rank (Mantel-Cox) 22.083 3 .000
Test of equality of survival distributions for the different levels of CKD Anaemia Multimorbidity.
aRisk of "death from any cause"BMC Cardiovascular Disorders 2009, 9:51 http://www.biomedcentral.com/1471-2261/9/51
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patients with cardiovascular disease. To our knowledge,
this is the first description of the comparative risks associ-
ated with anaemia and chronic kidney disease in a pri-
mary care population with established cardiovascular
disease. The cohort comprised the complete cardiovascu-
lar population of a randomly selected sample of practices
and despite the difficulties of detailed data collection in
primary care very few patients were lost to follow-up
(2.6%). However, our study had a number of limitations.
Firstly, the cohort was not formed as a de novo popula-
tion with multimorbidity but rather a cardiovascular pop-
ulation in which multimorbidity was then identified.
Secondly, although level of multimorbidity appears to
discriminate prognosis between patients with established
cardiovascular disease, it is difficult to identify the differ-
ent elements of this association as much of chronic kidney
disease and anaemia may have their origin in cardiovascu-
lar disease. Thirdly, the study sample was overwhelmingly
Caucasian and the prevalence of chronic kidney disease in
this study may underestimate the prevalence in other eth-
nic groups. Fourthly, the sample sizes of the patient
groups with anaemia were small (n = 38 and n = 37) in
comparison to the other patient groups used in this study.
Finally, lack of availability of serum creatinine and full
blood count data in the community setting excluded
some patients from the study and shortened follow-up in
others. This reflects the limitation in data-availability
which can hamper chronic disease management and
indeed research within primary care generally.
Comparison with existing literature
Population surveys suggest that 30% of adults suffer from
more than one chronic health problem [20]. In the US,
the prevalence of multimorbidity is estimated at 65% in
those over 65 years of age [21]. There is a large discrepancy
between the prevalence of multimorbidity in the popula-
tion and the number of research studies devoted to it,
especially in primary care [22]. The one year mortality of
elderly patients with moderate chronic kidney disease
(serum creatinine 220-343 μmol/L) after myocardial inf-
arction is nearly tripled compared to those with normal
renal function (66% vs. 24%) [23]. Similarly, survival is
noticeably reduced in patients with anaemia both 1
month [24] and 1 year [25] after myocardial infarction.
The current study confirms that in patients with CVD both
CKD and anaemia have an additive effect in increasing
risk of death.
The current data are consistent with what has been dem-
onstrated elsewhere in patients with chronic kidney dis-
ease -- that anaemia is strongly associated with both
cardiovascular disease [26,27] and adverse clinical out-
comes including mortality [28-30]. The cumulative effect
of multimorbidity in CVD and CKD has also been dem-
onstrated with diabetic patients [16] and it is suspected
that diabetes would play a further additive role on nega-
tive clinical outcomes in patients with highest levels of
comorbidity.
Implications for future research and clinical practice
The absence of national or indeed international guide-
lines for the management of patients with multimorbidity
highlights the gulf which exists between the complexity of
disease and the reductionism inherent in disease-specific
guideline development. Specific to the comorbidities
involved in this study, some authors of cardiorenal anae-
mia syndrome literature hypothesize that the pathophys-
iological processes may differ between anaemia and CKD
when compared with anaemia and heart failure [10].
These differences may account for discrepancies that have
been shown in the results from large multi-centre rand-
omized trials and smaller trials of anaemia correction
therapy. Many of the larger trials with CKD patients dem-
onstrated no improvement with anaemia correction ther-
apy [31-33], whereas smaller studies were able to
demonstrate that anaemia correction improved NYHA
class and renal function in patients with heart failure
[34,35]. It is also clear that recent studies involving
patients with CKD [3,33] or cancer with anaemia have
raised concerns about potential harm from aggressive
anaemia correction. There are currently two large ongoing
trials that are attempting to resolve the divergence in the
results of anaemia therapy in CKD and patients with heart
failure [36,37]. There is a great deal of uncertainty that
exists surrounding the management of anaemia in
patients with both chronic kidney disease and cardiovas-
cular disease. Although targets for haemoglobin levels in
patients with CKD have been confirmed [38,39] anaemia
Table 3: aAdjusted hazard ratios for death endpoint among 
patients according to presence of anaemia and CKD
Classification Death from any cause
exp() ((95% C.I.)
CVD only 1.00
CVD + CKD .685 1.985 (0.990,3.980)
CVD + Anaemia .857 2.356 (0.780,7.114)
CVD + CKD + Anaemia 1.467 4.334 (1.759,10.681)
Total number of patients = 617.
aThe Cox proportional hazards model used in the above analysis 
adjusted for the following covariates: age, gender, GMS status, 
smoking status, systolic blood pressure, diastolic blood pressure, total 
cholesterol level, previous myocardial infarction, angina, heart failure, 
stroke, peripheral vascular disease, thromboembolic events, prior 
percutaneous coronary intervention, prior coronary artery bypass 
grafting, use of aspirin, B-Blocker, Lipid-lowering agent or ACE 
inhibitor.
ˆ β ˆ βBMC Cardiovascular Disorders 2009, 9:51 http://www.biomedcentral.com/1471-2261/9/51
Page 6 of 8
(page number not for citation purposes)
correction therapy may not be commonly practiced in
light of discrepancies between the results discussed above.
It may be due to the uncertainty of target haemoglobin
levels in multimorbidity patients that anaemia diagnosis
and treatment is surprisingly low in CKD patients [40]. It
is also possible that primary care physicians are prioritiz-
ing treatment of CVD over CKD and anaemia in this pop-
ulation [41]. Patients with these co-morbidities may also
suffer from late referral to secondary care [42]. We have
demonstrated that even milder levels of anaemia may be
associated with negative health outcomes in patients with
CKD and/or CVD.
Conclusion
In patients with cardiovascular disease, the presence of
chronic kidney disease carries an increased mortality risk
which increases in an additive way with the addition of
anaemia. These results suggest that early primary care
diagnosis and management of this high risk group may be
worthwhile. In order to develop effective management
strategies, however, innovative approaches to the study of
this population are required and due to the diversity of
patients and medical conditions encountered, primary
care offers an ideal setting for this to take place.
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